Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Combined With Bevacizumab in HER-2 Negative Advanced Breast Cancer
NCT05398861Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2022; status: recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05398861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398861.